130 related articles for article (PubMed ID: 38582568)
1. Severe reactivation of seronegative occult hepatitis B after chemotherapy for lymphoma.
Torres HA; Mustafayev K; Nastoupil LJ; Shelburne SA
Lancet; 2024 Apr; 403(10434):1372-1373. PubMed ID: 38582568
[No Abstract] [Full Text] [Related]
2. Prospective evaluation of seropositive occult hepatitis B viral infection in lymphoma patients receiving chemotherapy.
Cheung WI; Lin SY; Leung VK; Fung KS; Lam YK; Lo FH; Chau TN
Hong Kong Med J; 2011 Oct; 17(5):376-80. PubMed ID: 21979474
[TBL] [Abstract][Full Text] [Related]
3. Reactivation of Occult Hepatitis B Virus Infection 27 Months after the End of Chemotherapy Including Rituximab for Malignant Lymphoma.
Muraishi J; Shibata M; Honma Y; Hiura M; Abe S; Harada M
Intern Med; 2017; 56(15):1967-1971. PubMed ID: 28768965
[TBL] [Abstract][Full Text] [Related]
4. Transient reactivation of occult hepatitis B virus infection despite lamivudine prophylaxis in a patient treated for non-Hodgkin lymphoma.
Tonziello G; Pisaturo M; Sica A; Ferrara MG; Sagnelli C; Pasquale G; Sagnelli E; Guastafierro S; Coppola N
Infection; 2013 Feb; 41(1):225-9. PubMed ID: 22855434
[TBL] [Abstract][Full Text] [Related]
5. Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial.
Huang H; Li X; Zhu J; Ye S; Zhang H; Wang W; Wu X; Peng J; Xu B; Lin Y; Cao Y; Li H; Lin S; Liu Q; Lin T
JAMA; 2014 Dec; 312(23):2521-30. PubMed ID: 25514302
[TBL] [Abstract][Full Text] [Related]
6. [Reactivation of hepatitis B virus in a patient treated for non-Hodgkin B diffuse large cell lymphoma with rituximab: about a case].
Houssou B; Massi RM; Camara M; Mifdal H; Nourichafi N; Zafad S; Oukkache B
Pan Afr Med J; 2015; 22():22. PubMed ID: 26664523
[TBL] [Abstract][Full Text] [Related]
7. [Hepatitis B virus reactivation in rituximab-treated patients: incidence and risk factors].
Gutiérrez García ML; Alonso Lopez S; Martín Rios MD; Sanmartin Fenollera P; Agudo Fernandez S; Fernández Rodriguez CM
Gastroenterol Hepatol; 2015 Jan; 38(1):1-6. PubMed ID: 25205080
[TBL] [Abstract][Full Text] [Related]
8. Tenofovir-induced severe hepatitis in occult hepatitis B reactivation.
Habib G; Nashashibi M
Dig Liver Dis; 2015 Oct; 47(10):898-9. PubMed ID: 26346266
[No Abstract] [Full Text] [Related]
9. Fatal reactivation of occult hepatitis B virus infection after rituximab and chemotherapy in lymphoma: necessity of antiviral prophylaxis.
Zhang B; Wang J; Xu W; Wang L; Ni W
Onkologie; 2010; 33(10):537-9. PubMed ID: 20926902
[TBL] [Abstract][Full Text] [Related]
10. Quantification of HBV core antibodies may help predict HBV reactivation in patients with lymphoma and resolved HBV infection.
Yang HC; Tsou HH; Pei SN; Chang CS; Chen JH; Yao M; Lin SJ; Lin J; Yuan Q; Xia N; Liu TW; Chen PJ; Cheng AL; Hsu C;
J Hepatol; 2018 Aug; 69(2):286-292. PubMed ID: 29551710
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis B reactivation after chemoimmunotherapy: screen before treatment.
Hwang JP; Ferrajoli A; Lok AS
Lancet; 2021 Feb; 397(10273):510. PubMed ID: 33549195
[No Abstract] [Full Text] [Related]
12. Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group.
Kim SJ; Hsu C; Song YQ; Tay K; Hong XN; Cao J; Kim JS; Eom HS; Lee JH; Zhu J; Chang KM; Reksodiputro AH; Tan D; Goh YT; Lee J; Intragumtornchai T; Chng WJ; Cheng AL; Lim ST; Suh C; Kwong YL; Kim WS
Eur J Cancer; 2013 Nov; 49(16):3486-96. PubMed ID: 23910494
[TBL] [Abstract][Full Text] [Related]
13. Prophylactic antiviral therapy for hepatitis B virus surface antigen-positive patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy.
Yamauchi N; Maruyama D; Choi I; Atsuta Y; Sakai R; Miyashita K; Moriuchi Y; Tsujimura H; Kubota N; Yamamoto G; Igarashi T; Izutsu K; Yoshida S; Kojima K; Uchida T; Inoue Y; Tsukamoto N; Ohtsuka E; Suzuki S; Inaguma Y; Ichikawa S; Gomyo H; Ushijima Y; Nosaka K; Kurata M; Tanaka Y; Ueda R; Mizokami M; Kusumoto S
Cancer Sci; 2021 May; 112(5):1943-1954. PubMed ID: 33576088
[TBL] [Abstract][Full Text] [Related]
14. Lymphocyte/monocyte ratio and cycles of rituximab-containing therapy are risk factors for hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma and resolved hepatitis B.
Wu CY; Hsiao LT; Chiou TJ; Gau JP; Liu JH; Yu YB; Wu YT; Liu CJ; Huang YC; Hung MH; Chen PM; Huang YH; Tzeng CH
Leuk Lymphoma; 2015; 56(8):2357-64. PubMed ID: 25459444
[TBL] [Abstract][Full Text] [Related]
15. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis.
Koo YX; Tay M; Teh YE; Teng D; Tan DS; Tan IB; Tai DW; Quek R; Tao M; Lim ST
Ann Hematol; 2011 Oct; 90(10):1219-23. PubMed ID: 21520001
[TBL] [Abstract][Full Text] [Related]
16. Fatal Hepatitis C after Chemotherapy in a Patient with Malignant Lymphoma: Possible Reactivation of Seronegative Occult Hepatitis C Virus Infection Due to Chemotherapy.
Miyashita K; Hongo Y; Nakashima A; Kato S; Kusano H; Morizono S; Higashi N
Intern Med; 2021 May; 60(10):1533-1539. PubMed ID: 33191319
[TBL] [Abstract][Full Text] [Related]
17. Viral Outcome in Patients with Occult HBV Infection or HCV-Ab Positivity Treated for Lymphoma.
Guarino M; Picardi M; Vitello A; Pugliese N; Rea M; Cossiga V; Pane F; Caporaso N; Morisco F
Ann Hepatol; 2017; 16(2):198-206. PubMed ID: 28233742
[TBL] [Abstract][Full Text] [Related]
18. High titers of anti-HBs prevent rituximab-related viral reactivation in resolved hepatitis B patient with non-Hodgkin's lymphoma.
Cho Y; Yu SJ; Cho EJ; Lee JH; Kim TM; Heo DS; Kim YJ; Yoon JH
J Med Virol; 2016 Jun; 88(6):1010-7. PubMed ID: 26531242
[TBL] [Abstract][Full Text] [Related]
19. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B.
Huang YH; Hsiao LT; Hong YC; Chiou TJ; Yu YB; Gau JP; Liu CY; Yang MH; Tzeng CH; Lee PC; Lin HC; Lee SD
J Clin Oncol; 2013 Aug; 31(22):2765-72. PubMed ID: 23775967
[TBL] [Abstract][Full Text] [Related]
20. Risk and prophylaxis strategy of hepatitis B virus reactivation in patients with lymphoma undergoing chemotherapy with or without rituximab.
Pei SN; Chen CH
Leuk Lymphoma; 2015 Jun; 56(6):1611-8. PubMed ID: 25248874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
